Before semaglutide and tirzepatide became household names, there was exenatide, a peptide with an origin story unlike almost anything else in modern pharmacology: it was isolated from the venom of the Gila monster, a desert lizard native to the southwestern United States.
An Unusual Discovery
In the early 1990s, researcher Dr. John Eng, working with Dr. Jean-Pierre Raufman, identified a peptide in Gila monster venom called exendin-4. The peptide activated the same receptor as the human hormone GLP-1, which the body normally releases after eating to help regulate blood sugar, but exendin-4 had a key structural difference: a single amino acid substitution at its N-terminus made it resistant to the enzyme DPP-4, which rapidly breaks down the body's own GLP-1 within minutes. That resistance meant exendin-4 could lower blood glucose in diabetic animal models and keep it lowered for hours, an effect the natural hormone can't sustain on its own.
From Venom to Approved Drug
Amylin Pharmaceuticals licensed exendin-4 in 1996 and developed a synthetic version, exenatide, through clinical trials over the following years. The FDA approved exenatide under the brand name Byetta in April 2005 for adults with type 2 diabetes, making it the first-in-class incretin mimetic, the first drug to prove that deliberately activating the GLP-1 receptor was a viable, approvable treatment strategy. The original formulation required injections twice daily before meals.
How It Compares to Later GLP-1 Drugs
Exenatide's effects were real but modest by today's standards: trials showed roughly 0.8 to 1.0 percentage point reductions in HbA1c (a measure of average blood sugar) and average weight loss in the range of 4 to 5 kilograms, alongside a twice-daily injection schedule. Semaglutide, approved more than a decade later, is a modified version of the human GLP-1 hormone itself rather than a lizard-venom-derived peptide, engineered for a much longer half-life that allows once-weekly dosing, and produces substantially greater average weight loss in obesity trials. Tirzepatide goes further still, activating both the GLP-1 and GIP receptors. Exenatide's clearance is also different: it's eliminated primarily through the kidneys rather than through the enzymatic degradation pathways that shape how other GLP-1 drugs are metabolized.
Why the History Matters
Exenatide isn't primarily a historical footnote; longer-acting formulations have continued to be prescribed for type 2 diabetes. But its real significance is what it proved: that a peptide could be engineered or discovered to safely and durably activate the GLP-1 pathway in humans, opening the door to the entire drug class that followed. Every GLP-1 and GLP-1/GIP therapy covered elsewhere on this site, from liraglutide through tirzepatide and retatrutide, exists downstream of the pharmacological proof of concept exenatide established two decades ago.
The Bottom Line
Exenatide represents the first successful translation of GLP-1 receptor science into an approved human therapy, and its unlikely natural source is a genuine and well-documented piece of pharmaceutical history. Patients with type 2 diabetes considering GLP-1-class medications today, whether an exenatide formulation or a newer option, should discuss which specific drug best fits their diagnosis, goals, and health history with their physician, since efficacy, dosing frequency, and side-effect profiles differ meaningfully across the class.